Inicio Zine News Dr. Reddy’s Announces the Launch of the Over-the-counter Store Brand Equivalent of...

Dr. Reddy’s Announces the Launch of the Over-the-counter Store Brand Equivalent of Mucinex® D Extended Release Tablets in Two Strengths in the U.S. Market

3
0

HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of an over-the-counter (OTC) store-brand equivalent of Mucinex® D Extended Release Tablets in two strengths—Guaifenesin 600 mg and Pseudoephedrine HCl 60 mg, and Guaifenesin 1200 mg and Pseudoephedrine HCl 120 mg—in the United States market, as approved by the U.S. Food and Drug Administration (USFDA).

“We are excited to bring first to market the store-brand equivalent of Mucinex® D Maximum Strength Extended Release Tablets. These launches illustrate our continued commitment to the OTC business and our growing portfolio in the cough, cold and allergy category”

Tweet this

Dr. Reddy’s OTC Guaifenesin and Pseudoephedrine HCl is used to help loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive; temporarily relieve nasal congestion due to common cold, hay fever, and upper respiratory allergies; temporarily restore freer breathing through the nose; promote nasal and/or sinus drainage; and temporarily relieve sinus congestion and pressure.

“We are excited to bring first to market the store-brand equivalent of Mucinex® D Maximum Strength Extended Release Tablets. These launches illustrate our continued commitment to the OTC business and our growing portfolio in the cough, cold and allergy category,” says Milan Kalawadia, Senior Vice President and Head of US OTC and Specialty Rx Divisions, Dr. Reddy’s Laboratories.

The Mucinex® D brand and store brands had combined U.S. sales of approximately $71 million MAT for the most recent twelve months ending in May 2019 according to IRI*.

Dr. Reddy’s OTC Guaifenesin 1200 mg and Pseudoephedrine HCl 120 mg is available in 24-count packages.
Dr. Reddy’s OTC Guaifenesin 600 mg and Pseudoephedrine HCl 60 mg is available in 18- and 36-count packages.

Mucinex is a trademark of RB HEALTH (US) LLC

*IRI MAT May 2019
RDY-OTC-0619

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com



Dejar una respuesta

Please enter your comment!
Please enter your name here

*